These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 14586677

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
    Suñer M, Guerrero A, Montes R, Rivera M, Ruiz A, Martínez-García M, Pérez-Valdivia MA, Mateos J.
    Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
    [Abstract] [Full Text] [Related]

  • 5. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
    Hervás JG, Prados D, Cerezo S.
    Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H, Koiwa F, Shishido K, Kinugasa E.
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM, Reiner D, Kern M, Burke S.
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A.
    Nephron Clin Pract; 2004 Dec; 97(1):c17-22. PubMed ID: 15153763
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
    Nagano N, Fukushima N.
    Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J, Piecha G, Kokot F, Wiecek A.
    J Nephrol; 2003 Nov; 16(5):710-5. PubMed ID: 14733418
    [Abstract] [Full Text] [Related]

  • 20. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK.
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.